Cancer Biomarkers Conference VIII

Cancer Biomarkers Conference VIII is organized by The University of Texas MD Anderson Cancer Center and will be held from Oct 23 - 24, 2026 at UT MD Anderson Cancer Center, Houston, Texas, United States of America.

Description:
The Cancer Biomarkers Conference VIII at The University of Texas MD Anderson Cancer Center brings together experts in pathology, oncology, molecular diagnostics, and translational research to explore the rapidly evolving role of biomarkers in cancer diagnosis, prognosis, and therapy selection. This conference highlights how advances in molecular pathology, artificial intelligence, liquid biopsy technologies, and next-generation sequencing are transforming precision oncology. Through expert presentations and interdisciplinary discussion, the meeting provides an interactive forum where clinicians, scientists, and laboratory professionals can exchange knowledge and explore strategies to translate biomarker discoveries into improved patient care.

Topics will include:

• Emerging cancer biomarkers in hematologic malignancies and solid tumors, including leukemia, bladder, lung, and liver cancers
• Advances in molecular diagnostics, liquid biopsy, and next-generation sequencing are shaping precision oncology
• Integration of artificial intelligence and digital pathology in biomarker discovery and diagnostic workflows
• Translational applications of biomarkers in disease monitoring, therapeutic decision-making, and targeted treatment strategies
• Implementation of biomarker testing and collaborative innovation between academia and industry to advance precision cancer care

Learning Objectives:
After participating in this conference, learners should be able to:

• Recognize emerging cancer biomarkers and their role in diagnosis, prognosis, and treatment selection across multiple cancer types
• Interpret advances in molecular diagnostics and next-generation sequencing to support precision oncology strategies
• Evaluate biomarker-driven therapies and targeted treatments that are shaping modern cancer care
• Assess the growing role of artificial intelligence, digital pathology, and translational research in advancing biomarker-guided clinical practice